EA200501019A1 - Противораковое лекарственное средство, фармацевтическая композиция и способ ингибирования размера опухоли (варианты) на его основе - Google Patents

Противораковое лекарственное средство, фармацевтическая композиция и способ ингибирования размера опухоли (варианты) на его основе

Info

Publication number
EA200501019A1
EA200501019A1 EA200501019A EA200501019A EA200501019A1 EA 200501019 A1 EA200501019 A1 EA 200501019A1 EA 200501019 A EA200501019 A EA 200501019A EA 200501019 A EA200501019 A EA 200501019A EA 200501019 A1 EA200501019 A1 EA 200501019A1
Authority
EA
Eurasian Patent Office
Prior art keywords
options
pharmaceutical composition
tumor size
inhibiting tumor
tract medicine
Prior art date
Application number
EA200501019A
Other languages
English (en)
Inventor
Элан Джил
Дорин Липейдж
Original Assignee
Байоджен Айдек Эмэй Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Эмэй Инк. filed Critical Байоджен Айдек Эмэй Инк.
Publication of EA200501019A1 publication Critical patent/EA200501019A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение относится к комбинированным терапевтическим препаратам, которые содержат агент, который активирует передачу сигнала рецептора лимфотоксина-β, и представляют собой комбинацию такого агента с одним или более химиотерапевтическими агентами, а также относится к терапевтическим способам, которые предполагают использование этих комбинированных терапевтических препаратов, обладающих сверхаддитивным эффектом на ингибирование опухоли.
EA200501019A 2002-12-20 2003-12-22 Противораковое лекарственное средство, фармацевтическая композиция и способ ингибирования размера опухоли (варианты) на его основе EA200501019A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43518502P 2002-12-20 2002-12-20
PCT/US2003/041243 WO2004058183A2 (en) 2002-12-20 2003-12-22 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents

Publications (1)

Publication Number Publication Date
EA200501019A1 true EA200501019A1 (ru) 2006-06-30

Family

ID=32682180

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501019A EA200501019A1 (ru) 2002-12-20 2003-12-22 Противораковое лекарственное средство, фармацевтическая композиция и способ ингибирования размера опухоли (варианты) на его основе

Country Status (16)

Country Link
US (1) US20060134102A1 (ru)
EP (1) EP1585547A4 (ru)
JP (1) JP2006513225A (ru)
KR (1) KR20050094819A (ru)
CN (1) CN1753692A (ru)
AU (1) AU2003303339A1 (ru)
BR (1) BR0317573A (ru)
CA (1) CA2509495A1 (ru)
EA (1) EA200501019A1 (ru)
IS (1) IS7900A (ru)
MX (1) MXPA05006663A (ru)
NO (1) NO20053529L (ru)
PL (1) PL377611A1 (ru)
RS (1) RS20050481A (ru)
WO (1) WO2004058183A2 (ru)
ZA (1) ZA200505543B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CZ20031307A3 (cs) * 2000-10-13 2003-10-15 Biogen, Inc. Humanizované protilátky k lymfotoxinovému beta receptoru
AU2003256299A1 (en) * 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
EP1539793A4 (en) * 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
EP1583503A4 (en) * 2002-12-20 2006-08-09 Biogen Idec Inc POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF
NZ544924A (en) * 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
NZ550518A (en) 2004-03-23 2009-11-27 Biogen Idec Inc Agents that cross link TNF receptors for treating cancer
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
AU2007258189A1 (en) * 2006-06-15 2007-12-21 Biogen Idec Ma Inc. Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
MX2009003774A (es) 2006-10-12 2009-04-22 Genentech Inc Anticuerpos para linfotoxina-alfa.
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
SG154441A1 (en) * 2006-10-20 2009-08-28 Biogen Idec Inc Treatment of demyelinating disorders
AU2008275589B2 (en) * 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
SG10201912792YA (en) 2015-10-06 2020-02-27 Univ Minnesota Therapeutic compounds and methods
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
WO2019238966A1 (en) * 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
CA3164226A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
CN115057938B (zh) * 2022-06-24 2023-01-06 广东菲鹏制药股份有限公司 抗新型冠状病毒人源化多价结合蛋白及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2211443A1 (en) * 1995-01-26 1996-08-01 Biogen, Inc. Lymphotoxin-.alpha./.beta. complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
ES2268727T3 (es) * 1996-10-25 2007-03-16 Biogen Idec Ma Inc. Receptores solubles de linfotoxina b, anticuerpos anti-receptor de linfotoxina y anticuerpos anti-ligandos de linfotoxina como agentes terapeuticos para el tratamiento de enfermedades inmunologicas.
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
CZ20031307A3 (cs) * 2000-10-13 2003-10-15 Biogen, Inc. Humanizované protilátky k lymfotoxinovému beta receptoru
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
EP1539793A4 (en) * 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
EP1583503A4 (en) * 2002-12-20 2006-08-09 Biogen Idec Inc POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
NZ550518A (en) * 2004-03-23 2009-11-27 Biogen Idec Inc Agents that cross link TNF receptors for treating cancer

Also Published As

Publication number Publication date
NO20053529L (no) 2005-09-20
CA2509495A1 (en) 2004-07-15
KR20050094819A (ko) 2005-09-28
WO2004058183A3 (en) 2004-12-09
CN1753692A (zh) 2006-03-29
ZA200505543B (en) 2006-12-27
JP2006513225A (ja) 2006-04-20
EP1585547A2 (en) 2005-10-19
US20060134102A1 (en) 2006-06-22
PL377611A1 (pl) 2006-02-06
NO20053529D0 (no) 2005-07-19
RS20050481A (en) 2007-08-03
AU2003303339A1 (en) 2004-07-22
EP1585547A4 (en) 2006-10-25
MXPA05006663A (es) 2005-09-30
WO2004058183A2 (en) 2004-07-15
BR0317573A (pt) 2005-11-22
IS7900A (is) 2005-06-20

Similar Documents

Publication Publication Date Title
EA200501019A1 (ru) Противораковое лекарственное средство, фармацевтическая композиция и способ ингибирования размера опухоли (варианты) на его основе
BR0306872A (pt) Composições e métodos de tratamento envolvendo agonistas do receptor-gama ativado pelo proliferador de peroxissoma e inibidores seletivos da ciclooxigenase-2
BRPI0415858A (pt) compostos de medicamentos terapêuticos modificados por tocoferol
EA200501586A1 (ru) Фармацевтические продукты
DK1033981T3 (da) Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet
AU2003280087A8 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
CY1109661T1 (el) 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
WO2003080582A3 (de) Fredericamycin-derivate
CY1112738T1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
EA200601524A1 (ru) Альфа-излучающие частицы гидроксиапатита
HUP0300590A2 (hu) Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
NO20055838L (no) Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav
BR0207487A (pt) Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
HUP0203241A2 (hu) Heterotrimer G-fehérje jelátvitel inhibitor és egy rákellenes hatóanyag-kombináció alkalmazása rákbetegség gyógyítására
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
EA200970353A1 (ru) Комбинированное лекарственное средство
EA200501223A1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
TR200402230T4 (tr) O-ikameli 6-metil-tramadol-türevleri
HUP0202931A2 (hu) Egy gyógyszerészetileg hatásos összetétel és a beadására szolgáló készülék